|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-4.00/-2.07
|
企业价值
69.42M
|
资产负债 |
每股账面净值
7.41
|
现金流量 |
现金流量率
--
|
损益表 |
收益
0
|
每股收益
--
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/21 19:46 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally,targeting novel pathways at the interface of immunity and metabolism. It operates in one reportable segment of operations and manages. The company's pipeline includes NX-13, LABP-66, LAPB-73, LABP-69. The company's current focus and lead product candidate is NX-13, a novel, oral, gut-selective, NLRX1 agonist. |